[go: up one dir, main page]

YU24201A - Aerosolizable dry powder particles resistant to hygroscopic growth - Google Patents

Aerosolizable dry powder particles resistant to hygroscopic growth

Info

Publication number
YU24201A
YU24201A YU24201A YU24201A YU24201A YU 24201 A YU24201 A YU 24201A YU 24201 A YU24201 A YU 24201A YU 24201 A YU24201 A YU 24201A YU 24201 A YU24201 A YU 24201A
Authority
YU
Yugoslavia
Prior art keywords
dry powder
powder particles
hygroscopic growth
particles resistant
growth
Prior art date
Application number
YU24201A
Other languages
Serbo-Croatian (sh)
Inventor
Andrew Clark
Mei-Chang Kuo
Cecily Lalor
Barry John Aldous
Original Assignee
Inhale Therapeutic Systems Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inhale Therapeutic Systems Inc. filed Critical Inhale Therapeutic Systems Inc.
Publication of YU24201A publication Critical patent/YU24201A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Inorganic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)

Abstract

The present invention is directed to particulate compositions and methods for delivering an active agent to the lung of a human patient. The active agent formulation is in dry powder form and exhibits (i) low moisture sorption, and (ii) a resistance to hygrosscopic growth, particularly under simulated lung conditions.
YU24201A 1998-09-14 1999-09-13 Aerosolizable dry powder particles resistant to hygroscopic growth YU24201A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10016398P 1998-09-14 1998-09-14

Publications (1)

Publication Number Publication Date
YU24201A true YU24201A (en) 2003-08-29

Family

ID=22278404

Family Applications (1)

Application Number Title Priority Date Filing Date
YU24201A YU24201A (en) 1998-09-14 1999-09-13 Aerosolizable dry powder particles resistant to hygroscopic growth

Country Status (44)

Country Link
EP (1) EP1117442A1 (en)
JP (1) JP2002524535A (en)
KR (1) KR20010075063A (en)
CN (1) CN1317977A (en)
AP (1) AP1374A (en)
AR (1) AR022090A1 (en)
AU (1) AU753014B2 (en)
BG (1) BG105430A (en)
BR (1) BR9913722A (en)
CA (1) CA2343920A1 (en)
CO (1) CO5130023A1 (en)
CZ (1) CZ2001829A3 (en)
DZ (1) DZ2892A1 (en)
EA (1) EA003476B1 (en)
EE (1) EE200100151A (en)
GE (1) GEP20043257B (en)
GT (1) GT199900156A (en)
HK (1) HK1042231A1 (en)
HN (1) HN1999000159A (en)
HR (1) HRP20010189A2 (en)
HU (1) HUP0103837A3 (en)
ID (1) ID28845A (en)
IL (2) IL141562A0 (en)
IS (1) IS5878A (en)
LT (1) LT4897B (en)
LV (1) LV12658B (en)
MA (1) MA25590A1 (en)
MY (1) MY129282A (en)
NO (1) NO20011251L (en)
NZ (1) NZ510168A (en)
OA (1) OA11781A (en)
PA (1) PA8481901A1 (en)
PE (1) PE20001061A1 (en)
PL (1) PL195574B1 (en)
SA (1) SA99200718B1 (en)
SK (1) SK3442001A3 (en)
TN (1) TNSN99173A1 (en)
TR (1) TR200101182T2 (en)
TW (1) TWI226248B (en)
UA (1) UA76085C2 (en)
UY (1) UY25711A1 (en)
WO (1) WO2000015262A1 (en)
YU (1) YU24201A (en)
ZA (1) ZA200101995B (en)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6956021B1 (en) 1998-08-25 2005-10-18 Advanced Inhalation Research, Inc. Stable spray-dried protein formulations
JP4874483B2 (en) 1999-06-09 2012-02-15 ロバート イー． シーバース Supercritical fluid assisted nebulization and bubble drying
US6475468B2 (en) * 2001-02-15 2002-11-05 Aeropharm Technology Incorporated Modulated release particles for aerosol delivery
CA2446904A1 (en) * 2001-05-24 2003-04-03 Alexza Molecular Delivery Corporation Delivery of drug esters through an inhalation route
EG24184A (en) 2001-06-15 2008-10-08 Otsuka Pharma Co Ltd Dry powder inhalation system for transpulmonary
CA2465675C (en) 2001-11-20 2008-06-10 Advanced Inhalation Research, Inc. Improved particulate compositions for pulmonary delivery
US7759506B2 (en) 2002-02-25 2010-07-20 Diffusion Pharmaceuticals Llc Bipolar trans carotenoid salts and their uses
UA83341C2 (en) 2002-02-25 2008-07-10 Дифьюжен Фармасьютикалз Ллк Trans carotenoid bipolar salts and uses thereof
AU2003232081B2 (en) * 2002-07-03 2009-02-05 Brandeis University Central airway administration for systemic delivery of therapeutics
CA2511385A1 (en) * 2002-12-19 2004-07-22 Pharmacia Corporation Non-hygroscopic formulation comprising a hydroscopic drug
DE10338403A1 (en) * 2003-08-18 2005-03-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Powder formulation containing the CGRP antagonist 1- [N 2 - [3,5-dibromo-N - [[4- (3,4-dihydro-2 (1 H) -oxoquinazolin-3-yl] -1-piperidinyl] carbonyl] -D-tyrosyl] -L-lysyl] -4- (4-pyrindinyl) piperazine, process for its preparation and its use as inhalant
GB0327723D0 (en) * 2003-09-15 2003-12-31 Vectura Ltd Pharmaceutical compositions
US20070020299A1 (en) 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
ES2909080T3 (en) 2004-04-23 2022-05-05 Cydex Pharmaceuticals Inc DPI formulation containing sulfoalkyl ether cyclodextrin
US8030350B2 (en) 2005-02-24 2011-10-04 Diffusion Pharmaceuticals Llc Trans carotenoids, their synthesis, formulation and uses
BRPI0608844A2 (en) * 2005-03-09 2010-02-02 Ono Pharmaceutical Co particle and preparation containing the particle
ES2526903T3 (en) 2005-10-26 2015-01-16 Cydex Pharmaceuticals, Inc. Sulfoalkyl cyclodextrin compositions and methods of preparation thereof
US7629331B2 (en) 2005-10-26 2009-12-08 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof
US20080035143A1 (en) * 2006-08-14 2008-02-14 Sievers Robert E Human-powered dry powder inhaler and dry powder inhaler compositions
KR20090081407A (en) * 2006-10-25 2009-07-28 다이닛본 스미토모 세이야꾸 가부시끼가이샤 Anti-caking granular formulation
EP1925295A1 (en) * 2006-11-22 2008-05-28 Boehringer Ingelheim Pharma GmbH & Co. KG Stable powder formulation containing a new antichinolinergic agent
MX2009010988A (en) 2007-04-13 2010-03-15 Diffusion Pharmaceuticals Llc Use of bipolar trans carotenoids as a pretreatment and in the treatment of peripheral vascular disease.
US12370352B2 (en) 2007-06-28 2025-07-29 Cydex Pharmaceuticals, Inc. Nasal and ophthalmic delivery of aqueous corticosteroid solutions
MX2010004803A (en) 2007-10-31 2010-09-09 Diffusion Pharmaceuticals Llc A new class of therapeutics that enhance small molecule diffusion.
US9610343B2 (en) * 2009-05-20 2017-04-04 Aeras Global Tb Vaccine Foundation Stable, spray dryed, immunogenic, viral compositions
EP2445339B1 (en) 2009-06-22 2019-08-07 Diffusion Pharmaceuticals LLC Diffusion enhancing compound and its use with a thrombolytic
ES2654945T3 (en) 2010-06-02 2018-02-15 Diffusion Pharmaceuticals Llc Oral formulations of trans bipolar carotenoids
US9682096B2 (en) 2012-05-02 2017-06-20 Janssen R & D Ireland Polyinosinic-polycytidylic acid (poly (I:C)) formulations for the treatment of upper respiratory tract infections
WO2014074797A1 (en) * 2012-11-09 2014-05-15 Civitas Therapeutics, Inc. Ultra low density pulmonary powders
WO2015042352A1 (en) * 2013-09-20 2015-03-26 Virginia Commonwealth University Delivery of particles using hygroscopic excipients
CA2965759C (en) 2014-10-31 2023-12-12 Glaxosmithkline Intellectual Property Development Limited Powdered polypeptides with decreased disulfide impurities comprising divalent cationic materials
WO2017165667A1 (en) 2016-03-24 2017-09-28 Diffusion Pharmaceuticals Llc Use of bipolar trans carotenoids with chemotherapy and radiotherapy for treatment of cancer
US20220378727A1 (en) * 2021-05-14 2022-12-01 The University Of Hong Kong Dry powder formulations of tamibarotene for pulmonary and intranasal delivery

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3155573A (en) * 1958-05-06 1964-11-03 Benger Lab Ltd Inhalant composition and method of making same
ATE222754T1 (en) * 1992-06-12 2002-09-15 Teijin Ltd ULTRA FINE POWDER FOR INHALATION AND ITS PRODUCTION
US6524557B1 (en) * 1994-12-22 2003-02-25 Astrazeneca Ab Aerosol formulations of peptides and proteins
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
WO1998031346A1 (en) * 1997-01-16 1998-07-23 Massachusetts Institute Of Technology Preparation of particles for inhalation
US6086376A (en) * 1998-01-30 2000-07-11 Rtp Pharma Inc. Dry aerosol suspension of phospholipid-stabilized drug microparticles in a hydrofluoroalkane propellant

Also Published As

Publication number Publication date
UA76085C2 (en) 2006-07-17
IS5878A (en) 2001-03-05
CN1317977A (en) 2001-10-17
IL141562A0 (en) 2002-03-10
HUP0103837A3 (en) 2002-11-28
CZ2001829A3 (en) 2001-09-12
KR20010075063A (en) 2001-08-09
TWI226248B (en) 2005-01-11
PL346768A1 (en) 2002-02-25
EP1117442A1 (en) 2001-07-25
ZA200101995B (en) 2002-03-11
HUP0103837A2 (en) 2002-05-29
BG105430A (en) 2001-12-29
AP2001002093A0 (en) 2001-03-31
TR200101182T2 (en) 2001-09-21
CO5130023A1 (en) 2002-02-27
MY129282A (en) 2007-03-30
GT199900156A (en) 2001-03-07
WO2000015262A1 (en) 2000-03-23
HRP20010189A2 (en) 2005-04-30
PE20001061A1 (en) 2000-10-08
IL141562A (en) 2007-07-24
TNSN99173A1 (en) 2005-11-10
LV12658A (en) 2001-05-20
SA99200718B1 (en) 2006-11-04
AR022090A1 (en) 2002-09-04
CA2343920A1 (en) 2000-03-23
BR9913722A (en) 2001-05-29
LT2001021A (en) 2001-11-26
PA8481901A1 (en) 2002-04-25
UY25711A1 (en) 1999-11-17
AP1374A (en) 2005-02-28
LT4897B (en) 2002-02-25
EA003476B1 (en) 2003-06-26
ID28845A (en) 2001-07-05
LV12658B (en) 2001-09-20
NO20011251L (en) 2001-04-17
HK1042231A1 (en) 2002-08-09
SK3442001A3 (en) 2001-11-06
JP2002524535A (en) 2002-08-06
AU753014B2 (en) 2002-10-03
EE200100151A (en) 2002-06-17
MA25590A1 (en) 2002-12-31
GEP20043257B (en) 2004-06-25
OA11781A (en) 2005-07-26
DZ2892A1 (en) 2003-12-15
AU6039799A (en) 2000-04-03
EA200100300A1 (en) 2001-10-22
NO20011251D0 (en) 2001-03-13
PL195574B1 (en) 2007-10-31
HN1999000159A (en) 1999-11-11
NZ510168A (en) 2003-09-26

Similar Documents

Publication Publication Date Title
MY129282A (en) Aerosolizable particles resistant to hygroscopic growth
NZ511527A (en) Dry powder for inhalation
MY129112A (en) Flow resistance modulated aerosolized active agent delivery
HU9201521D0 (en) Stimulating unit containing nicotine
GB1484781A (en) Compositions for dental treatment
CA2412561A1 (en) Highly efficient delivery of a large therapeutic mass aerosol
PL343342A1 (en) Particulate active agent support for pulmonary application
NZ333724A (en) Enhancing lean tissue mass and bone mineral content by the administration of calcium compositions
ATE150310T1 (en) ORAL SUSPENSION CONSISTING OF STABILIZED ROCK POWDER OF A HYDRATED CEPHALOSPORIN
AU6611998A (en) Therapeutic powder formulation for pulmonary administration, containing crystalline insulin
ID22883A (en) FORMULATION FOR INHALATION THAT HAS OVERPRESSED HOUSING DENSITY BETWEEN 0.28 TO 038 G / ML AND CONTAINS BUDESONIDE
IS5109A (en) New inhalation formulation in bulk with a mass of 0.28 to 0.38 g / ml containing formoterol
WO2001085188A3 (en) Use of echinacea as a hematinic agent
WO2005039288A3 (en) An insectidcidal composition with enhanced synergistic activity
SE8300495D0 (en) IMPROVEMENTS IN OR RELATING TO NASAL PHARMACEUTICAL COMPOSITIONS
TH51990A3 (en) Release of the dry powdered active ingredient.